Incidence of skeletal muscle disorders after statins' treatment: Consequences in clinical and EMG picture

Neuroendocrinology Letters

Volumn 35, Issue 2, 2014, Pages 123-128

  Drobný, Michal ^a   Pullmann, Rudolf ^a   Odalos, Ivan ^a   Skerenova, Maria ^a   Sániov́a, Beata ^a  

^a University Teaching Hospital in Martin   (Slovakia)

Author keywords

"Statins' genes"; Agents myopathy; CLAM cholesterol lowering; Inflammation; Polymorphism; Rhabdomyolysis

Indexed keywords

ASPARTATE AMINOTRANSFERASE; ATORVASTATIN; CHOLESTEROL; CREATINE KINASE; CREATINE KINASE MB; CYTOCHROME P450; CYTOCHROME P450 2C8; CYTOCHROME P450 2C9; CYTOCHROME P450 SA/4; FLUINDOSTATIN; GLUCURONOSYLTRANSFERASE 1A1; GLUCURONOSYLTRANSFERASE 1A1 2B; ROSUVASTATIN; SOLUTE CARRIER ORGANIC ANION TRANSPORTER 1B1; UNCLASSIFIED DRUG;

ADULT; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CHOLESTEROL BLOOD LEVEL; CLINICAL FEATURE; CONTROLLED STUDY; CREATINE KINASE BLOOD LEVEL; DELTOID MUSCLE; ELECTROMYOGRAM; FATIGUE; FEMALE; GENETIC POLYMORPHISM; HEMODIALYSIS; HUMAN; HYPERCHOLESTEROLEMIA; INCIDENCE; KIDNEY DISEASE; KIDNEY FAILURE; LIVER DISEASE; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MOLECULAR GENETICS; MUSCLE ATROPHY; MUSCLE CRAMP; MUSCLE SPASM; MUSCLE WEAKNESS; MYALGIA; MYOGLOBINURIA; MYOPATHY; MYOSITIS; PLEIOTROPY; RHABDOMYOLYSIS; SIDE EFFECT; TREATMENT OUTCOME;

AGED; ELECTROMYOGRAPHY; FATTY ACIDS, MONOUNSATURATED; FEMALE; FLUOROBENZENES; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; INCIDENCE; INDOLES; MALE; MIDDLE AGED; MUSCULAR DISEASES; POLYMORPHISM, GENETIC; PYRIMIDINES; RHABDOMYOLYSIS; SULFONAMIDES;

EID: 84903124889     PISSN: 0172780X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (25)

1. AISheKhlee A, Hachwi R, Jaberi MM, Katirji B (2005). The electromyographic features of acute rhabdomyolysis. J Clin Neuromusc Dis. 6: 114-118.
2. Antons KA, Willians CD, Baker SK, Phillips PS (2006). Clinical perspectives of statin-induced rhabdomyolysis. Am J Med. 119: 500-409.
3. Campbell WW (2006). Statin myopathy: the iceberg or its tip? Muscle Nerve. 34: 387-390.
4. Carr DF, Meara H O, Jorgensen AL, Campbell J, Hobbs M, McCann G, van Staa T and Pirmohamed M (2013). SLCO 1B1 Genetic Variant Associated with Statin - Induced Myopathy: A Proof-of-Concept Study Using the Clinical Practice Research Datalink. Clinical Pharmacology & Therapeutics. 94 (6): 695-699.
5. 145) in Subjects with Hypercholesterolemia Who are Intolerant of Statin Therapy. Clin Cardiol. 37(3): 131-9.
6. De Luca A, Tricarico D, Pierno S, et al. (1994). Aging and chloride channel regulation in rat fast-twitch muscle fibers. Pflugers Arch. 427: 80-85. (Pubitemid 24131557)
7. Demyanets S, Kaun C, Pfaffenberger S, Hohensinner PJ, Rega G, Pammer J, Maurer G, Huber K, and Wojta J (2006). Hydroxymethylglutaryl-coenzyme A reductase inhibitors induce apoptosis in human cardiac myocytes in vitro. Biochem Pharmacol. 71: 1324-1330.
8. Fernandez G, Spatz ES, Jablecki Ch, Phillips PS (2014). Statin myopathy: A common dilemma not reflected in clinical trials. Cleveland Clinic Journal of Medicine. 78(6): 393-399.
9. Fraxino de Almeida D, Valente Lissa T, Mentor Neves Couto Melo AC Jr (2008). Myotonic potentials in statin-induced rhabdomyolysis. Arq. Neuro-Psiquiat. 66 (4) Sao Paulo Dec. 2008.
10. Johnson JE, Zimmerman ML, Daleke DL, et al. (1998). Lipid structure and not membrane structure is the major determinant in the regulation of protein kinase C by phosphatidylserine. Biochemistry. 37: 12020-12025. (Pubitemid 28411284)
11. Littlefield N, Beckstrand R, Luthy K (2014). Statin's effect on plasma levels of Coenzyme Q 10 and Improvement in myopathy with supplementation. Journal of the American Association of Nurse Practitioners 26(2): 85-90.
12. London SF, Gross KF, Ringel SP (1991). Cholesterol-lowering agents myopathy (CLAM). Neurology. 41: 1159-1160.
13. Matzno S, Yasuda S, Juman S, Yamamoto Y, Nagareya-Ishida N, Tazuya-Murayama K, Nakabayashi T, and Matsuyama K (2005) Statin-induced apoptosis linked with membrane farnesylated Ras small G protein depletion, rather than geranylated Rho protein. J Pharm Pharmacol. 57: 1475-1484. (Pubitemid 350066991)
14. Meriggioli MN, Barboi AC, Rowin J, Cochran EJ (2001). HMG-CoA reductase inhibitor myopathy: clinical, electrophysiological, and pathologic data in five patients. J Clin Neuromusc Dis. 2: 129-134.
15. Mutoh T, Kumano T, Nakagawa H, and Kuriyama M (1999). Involvement of tyrosine phosphorylation in HMG-CoA reductase inhibitor-induced cell death in L6 myoblasts. FEBS Lett. 444: 85-89. (Pubitemid 29094643)
16. Nakahara K, Kuriyama M, Sonoda Y, et al. (1998). Myopathy induced by HMG-CoA reductase inhibitors in rabbits: a pathological electrophysiological, and biochemical study. Toxicol Appl Pharmacol. 152: 99-106. (Pubitemid 28498678)
17. Nakahara K, Kuriyama M, Yoshidome H, et al. (1992). Experimental simvastatin-induced myopathy in rabbits. J Neurol Sci. 113: 114-117.
18. Sacher J, Weigl L, Werner M, Szegedi C, and Hohenegger M (2005). Delineation of myotoxicity induced by 3-hydroxy-3-methylglutaryl CoA reductase inhibitors in human skeletal muscle cells. J Pharmacol Exp Ther. 314: 1032-1041. (Pubitemid 41205966)
19. Sathasivam S, Lecky B (2008). Statin induced myopathy. BMJ 337 (2286): 1159-1162.
20. Sonoda Y, Gotow T, Kuriyama M, Nakahara K, Akimura K, Osame M (1994). Electrical myotonia of rabbit skeletal muscles by HMG-CoA reductase inhibitors. Muscle Nerve. 17: 891-897. (Pubitemid 24235997)
21. Tavee J, Panettiere A (2004). Unmasking of hereditary myotonia due to simvastatin. Muscle Nerve. 30: 529.
22. Thompson PD et al. (2003): Statin-associated myopathy. JAMA. 289: 1681-90. (Pubitemid 37430274)
23. Tomlinson SS and Mangione KK (2005). Potential adverse effects of statins on muscle. Phys Ther. 85: 459-465. (Pubitemid 40586829)
24. Tsivgoulis G, Spengos K, Karandreas N (2006). Presymptomatic Neuromuscular Disorders Disclosed Following Statin Treatment. Arch Intern Med.166: 1519-1524. (Pubitemid 44125872)
25. Victor M, Sieb JP (1994). Myopathies due to drugs, toxins and nutritional deficiency. In Engel AG, Franzini-Armstrong C (eds). Myology, 2.Ed. New York: McGraw-Hill, 1697-1724.